Product Description:-
 
Triomune tablets contain 3 active ingredient, the antiretrovirals stavudine (30mg), lamivudine (150mg) and nevirapine (200mg), used in combination to treat HIV infection. 
Triomune is a fixed dose combination treatment for Human Immunodeficiency Virus (HIV) infection in adults. Triomune tablets are used to treat HIV patients who have already been treated with other HIV medications and have responded well to each of the drugs in the combination; and are also able to tolerate each of these medications, at the recommended doses without requiring a dose adjustment due to low weight. HIV impairs the immune system by attacking specific immune cells called CD4+ cells that are involved in fighting infection, which can lead to opportunistic life-threatening infection (infections that would not normally be harmful); also if too many CD4+ cells are destroyed this can result in acquired immune deficiency syndrome (AIDS). Triomune tablets prevent or slow down the ability of HIV to replicate and spread, which keeps the amount of virus (viral load) down to a low level; allowing the numbers of CD4+ cells to increase, so that the immune system can recover, reducing the risk of disease progression. Triple drug therapy with Triomune 30 makes it easier to take the medications regularly, which helps improve compliance and helps prevent resistance of HIV to individual drugs. 

Triomune tablets contain a combination of 3 antiretroviral drugs stavudine, lamivudine and nevirapine, which are effective only against RNA viruses (retroviruses) like Human Immunodeficiency Virus (HIV). These three drugs each work by inhibiting the action of the viral-specific enzyme reverse transcriptase (RT) which is needed for the virus to be able to replicate. Retroviruses convert RNA to DNA, which is then integrated into the DNA of infected immune cells so that the virus can replicate. Nevirapine in Triomune tablets is a dipyridodiazepine derivative non-nucleoside reverse transcriptase inhibitor (NNRTI); nucleosides are the precursors to the building blocks of DNA and RNA. Nevirapine in Triomune tablets acts by binding to a specific site on the RT enzyme, the enzyme's active site known as the NNRTI pocket, disrupting the catalytic site of the enzyme, and blocking its action in a manner that is noncompetitive with nucleosides. Stavudine and lamivudine are both nucleoside analogue reverse transcriptase inhibitors (NRTI), which means that they block the action of RT by competing with one of the nucleosides needed to transcribe the viral RNA into DNA, becoming incorporated into the chain of newly synthesized viral DNA and preventing it from growing (chain termination). Stavudine is an analogue of thymidine and lamivudine is an analogue of cytidine. The combined action of the three antiiretroviral drugs in Triomune tablets prevents the integration of the virus into the DNA of the infected CD4+ immune cell by 2 different mechanisms, which inhibits the replication of HIV so that no more virus can be produced and this reduces the viral load (amount of virus). Triomune 30 slows down the replication of HIV within your body but does not kill the virus already incorporated in the CD4+ cells or prevent the spread of the infection to others.